Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes.

[1]  G. Filippatos,et al.  Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , 2020, Circulation.

[2]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[3]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[4]  Lingling Xu,et al.  SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials , 2020, Cardiovascular Diabetology.

[5]  Shao‐Wei Chen,et al.  The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors , 2020, Cardiovascular Diabetology.

[6]  K. Naka,et al.  The management of atrial fibrillation in heart failure: an expert panel consensus , 2020, Heart Failure Reviews.

[7]  Sanjiv J. Shah,et al.  Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. , 2020, JAMA cardiology.

[8]  Deepak L. Bhatt,et al.  Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus , 2020, Circulation.

[9]  A. Rosengren,et al.  Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study , 2020, Cardiovascular Diabetology.

[10]  B. Borlaug,et al.  Left atrial myopathy in heart failure with preserved ejection fraction , 2020, European journal of heart failure.

[11]  G. Filippatos,et al.  Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial , 2019, American Journal of Nephrology.

[12]  J. Jalife,et al.  Atrial Myopathy , 2019, JACC. Basic to translational science.

[13]  U. Laufs,et al.  The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. , 2019, Biochemical pharmacology.

[14]  S. Boekholdt,et al.  Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial , 2019, American Journal of Cardiovascular Drugs.

[15]  A. Gillis,et al.  The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights , 2019, Front. Physiol..

[16]  Wei Jiang,et al.  Chronic Kidney Disease Increases Atrial Fibrillation Inducibility: Involvement of Inflammation, Atrial Fibrosis, and Connexins , 2018, Front. Physiol..

[17]  D. Singer,et al.  Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. , 2017, Journal of the American College of Cardiology.

[18]  G. Lip,et al.  Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care , 2017, Journal of the American Heart Association.

[19]  U. Laufs,et al.  Rac1 GTPase regulates 11β hydroxysteroid dehydrogenase type 2 and fibrotic remodeling , 2017, The Journal of Biological Chemistry.

[20]  K. Phan,et al.  Atrial fibrillation: review of current treatment strategies. , 2016, Journal of thoracic disease.

[21]  U. Laufs,et al.  The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation* , 2014, The Journal of Biological Chemistry.

[22]  M. Allessie,et al.  Aldosterone promotes atrial fibrillation. , 2012, European heart journal.

[23]  J. McMurray,et al.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. , 2012, Journal of the American College of Cardiology.

[24]  Josef Coresh,et al.  Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study , 2011, Circulation.

[25]  K. Kuo,et al.  Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[26]  Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.